The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

Abstract

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAThe clinical effectiveness and costeffectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led...

Perspectives of pharmacogenetics approach to personalized tamoxifen therapy

“…Фармакоэкономический анализ, в который было включено 25 когортных исследований, показал отсутствие экономических преимуществ применения фармакогенети-ческого тестирования для персонализации дозирования тамоксифена [67].…”

CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?

“…The wide variety of responses and side effects of tamoxifen in different patients, questioned whether these differences result from an inter-individual genetic variability [11,12]. Since 2003, more than 20 studies tried to define the role of CYP2D6 polymorphisms in the efficacy of tamoxifen in females with breast cancer [13,14].…”

Estrogen Receptor α Roles in Breast Cancer Chemoresistance

“…Tamoxifen (selective estrogenreceptor modulators) is currently used in both premenopausal and postmenopausal breast cancer patients with ERα positive expression (Fisher et al, 1996;Fleeman et al, 2011). The Early Breast Cancer Trialists Collaborative Group meta-analysis of 194 randomized trials employing adjuvant chemotherapy and endocrine therapy demonstrated the 15-year breast cancer recurrence rate was reduced from 45% to 33% with use of tamoxifen, and reduction of breast cancer mortality by 35% (EBCTCG et al, 2008).…”